CS
RAPT

Candriam SCA’s RAPT Therapeutics RAPT Stock Holding History

Candriam SCA’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-39,158
Closed -$2.81M – 716
2024
Q1 		$2.81M Hold
39,158
– – 0.02% 449
2023
Q4 		$7.78M Hold
39,158
– – 0.05% 287
2023
Q3 		$5.21M Hold
39,158
– – 0.04% 306
2023
Q2 		$5.86M Sell
39,158
-2,142
-5% -$334K 0.04% 313
2023
Q1 		$5.58M Buy
41,300
+2,142
+5% +$433K 0.04% 341
2022
Q4 		$6.2M Hold
39,158
– – 0.04% 346
2022
Q3 		$7.54M Buy
39,158
+6,110
+18% +$1.16M 0.05% 320
2022
Q2 		$4.83M Buy
33,048
+13,327
+68% +$1.78M 0.04% 327
2022
Q1 		$3.47M Buy
+19,721
New +$3.72M 0.02% 423

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Candriam SCA's RAPT Position: Q2 2024 in Review

Candriam SCA sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 39,158 shares — an estimated $2.81M sold.

Candriam SCA first reported a position in RAPT in Q1 2022 and held it in 9 quarters. The position peaked at $7.78M in Q4 2023. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

  • Candriam SCA reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Candriam SCA sold 39,158 RAPT Therapeutics shares in Q2 2024, an estimated $2.81M.
  • Candriam SCA first reported a position in RAPT Therapeutics in Q1 2022 and held it in 9 quarters.
  • Candriam SCA's RAPT Therapeutics position peaked at $7.78M in Q4 2023.
  • 103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.